Ozempic

Losing weight with Ozempic is emptying the bodies. The beauty industry already knows how to fill them: with corpse fat

by

If you have ever lost weight, you have surely found yourself in this situation: the scale shows fewer kilos and your pants fit looser, but you have lost volume in unexpected (and unwanted) areas while others remain more or less the same. Spoiler: fat loss is not uniform. Whether you are on a diet or not, there is always the option of undergoing cosmetic surgery to remedy it, but of course: we are talking about a surgical intervention with all that it entails. Something has come to cover both gaps: that of avoiding surgery and those that allow you to lose weight: an injectable made from corpse fat. A “miraculous” injection with a peculiar ingredient. CNN account precisely the case of a 43-year-old lawyer from Los Angeles who had been considering breast augmentation for 20 years, but was held back by pain, recovery and the idea of ​​carrying “a strange bag” on her body. Last year he found the solution in AlloClae, which is the name of this injectable manufactured by Tiger Aesthetics. Designed for body contouring and soft tissue correction, the raw material is fat from donated corpses that, after following a treatment approved by the US Drug Agency and which, according to the manufacturer, eliminates the DNA of the deceased, is ready to be applied with an injection. Unlike classic fat grafts, in which healthcare personnel extract fat from the patient with luposuction and return it to another area, AlloClae arrives ready to use. Dead fat? Since May 2025, its manufacturer has reported more than 2,000 patients treated and on Reddit there is several threads with doubts. And be careful, the idea is not new: Renuvafrom the nonprofit MTF Biologics, has been injecting cadaver fat for more than a decade. But there is a substantial difference: size. While Renuva injects a maximum of three cubic centimeters, Alloclae reaches up to 25 cubic centimeters. Why now. Having a less invasive alternative to surgery for cosmetic touch-ups is always an incentive to carry them out, but the driving force behind this trend is GLP-1 drugs. In a society like the United States, where 11% use Ozempic-type medications to lose weight, many people face unwanted volume loss in parts of their body. According to the Gallup National Health and Well-Being Indexabout 11% of Americans currently use medications such as Ozempic or Wegovy to lose weight, and many patients lose unwanted facial or body volume. So after losing weight, these people seek to regain volume in places such as the face, chest or buttocks, says plastic surgeon Luis Macias. How it works. The procedure is applied in consultation, so there is no need to go to a hospital or general anesthesia. In just one hour it has already concluded and as Sandra accountthe instructions for the “postoperative” are “surprisingly simple.” Everything seems so simple that since January of this year it is not even necessary to be a plastic surgeon: nursing professionals and assistants can also apply it, although with certain restrictions. About legality and ethics. Before you die, you can give your consent for organ donation or to give your body to science. In the United States, the former are governed by federal law, but the body and tissues are a separate case whose legislation varies by state. That difference has already cost Tiger Aesthetics dearly: New York blocked distribution of the product, and the company has sued the state seeking at least $500,000 for lost sales, while it looks for new knitting banks in other states to continue growing. The problem is not so much legal as consent: in that form they give you does not appear explicitly if you want to donate your tissues to make Alloclae. It only allows you to check whether the donor authorizes their tissue to be used for research, commercial purposes, or without restrictions. That is to say: there are companies making money with a gesture intended as altruistic, without the donor really knowing what their body will become. In Xataka | Ozempic has radically redefined what we eat and how much we eat. And the ultra-processed ones are taking advantage of it In Xataka | We believed that with Ozempic, people who lost weight exercised more. we believed wrong Cover | Lobacheva Ina and Haberdoedas

The theory said that Ozempic was going to put an end to ultra-processed foods. The reality is that it has reinvented them

by

Whoever believed that Ozempic fever was going to be a hard blow for the manufacturers of ultra-processed products I was very wrong. And, as he recently explained in the BE food technology expert Beatriz Robles, the food industry never loses, it reinvents itself. As a result of the rise of this and other GLP-1 agonist drugs, the GLP-1 friendly foodproducts that are advertised for consumption by those who take these medications, but also for those who are thinking about trying to lose weight in other ways. The term arose among some nutritionists to refer to the foods that should be included in the diet of those who take Ozempic. However, the food industry has seen a breakthrough and has decided to convert classic ultra-processed products into alleged GLP-1 friendly options that not only give these people an adequate supply of nutrients. They also make their lives easier, because they don’t have to cook. With this and the appropriate doses of marketing, a fever is achieved similar to that of the famous black labels of foods rich in protein or the craze for superfoods with exotic origins. Because no, the superfoods that were never missing in your grandmother’s pantry don’t have such good marketing on social networks. Although they are even more superfoods. What is GLP-1? Before knowing what GLP-1 friendly foods are, we must start at the beginning: What is GLP-1? The answer, broadly speaking, is simple. It is a hormone that is synthesized naturally in the intestines, usually after eating. Its function is, on the one hand, control glucose levelssince it stimulates the production of insulin, a hormone that promotes its uptake in the cells, and decreases the production of glucagon, which does the opposite, as it stimulates the synthesis of glucose. On the other hand, GLP-1 reduces appetite by two different routes: directly in the brain, and also in the stomach, since it slows down gastric emptying. If the stomach empties more slowly, we will feel full for longer and perceive less feeling of hunger. The main problem with GLP-1 is that has a very short half-lifeof very few minutessince there is an enzyme that degrades it as soon as it reaches the bloodstream. Therefore, this is where GLP-1 analogues come into play. These drugs, including Ozempic, exert exactly the same effect as GLP-1, but for a longer duration. Traditionally they were designed to patients with diabetes. However, its effect on satiety led to its consumption also to treat overweight, either under medical advice or through self-medication. The rest is history. We live in a world increasingly dominated by Ozempic. And of course, that has led the food industry to reinvent itself. What are GLP-1 friendly foods? Mainly, Ozempic and other GLP-1 analogues help you lose weight due to their effect on reducing appetite. Therefore, nutritionists recommend that people who consume these medications adjust their diet appropriately. Since they will be eating less, they must further optimize the nutrients they consume. If we think about it, it’s simple: if you consume 10 dishes a day, adding all the meals, it is not so serious that one of them is not completely nutritious. On the other hand, if your appetite only allows you to eat three dishes, you should concentrate all your daily nutritional requirements there. Experts recommend above all focusing on protein and fiber. The first is necessary to strengthen muscle mass. When we eat less, we have a caloric deficit, which forces our body to consume energy by burning fat reserves. So far so good. It is what we look for if we want to lose weight. However, there comes a point where these are no longer enough, so muscle tissue also begins to be consumed. If we do not simultaneously consume a good supply of protein and we do strength exercisewe will lose a lot of muscle mass, with all the harm that entails. Regarding gastric emptying, on the one hand it is beneficial because it increases the feeling of satiety, but it also has a negative side: constipation. That is the reason why fiber consumption is so recommended. Nutritionist Lauren Manaker, for example, recommends salmon and eggs as sources of protein, as they are also very complete foods in other nutrients. Regarding fiber, he recommends prunes and berries. Additionally, for the upset stomach that Ozempic and other similar medications can sometimes cause, he recommends probiotics and ginger. Also, remember the importance of hydration. All of these could be considered basic GLP-1 friendly foods. However, the food industry has risen to the next level. What does the food industry propose? When appetite is reduced, the desire for certain ultra-processed products is often also reduced. For this reason, many brands have jumped on the bandwagon of GLP-1 friendly processed foods. They sell them as healthy options, which provide a very adequate amount of fiber and protein in one bite. However, this is somewhat similar to environmental greenwashing. Although it usually resorts to small environmental protection measures to divert attention from very harmful practices, with these foods the focus is on protein, fiber and vitamins, while on the other hand very inadequate doses of other nutrients are provided. Nutritionist Juan Revenga gives two examples in an article for The Country. To start, Nestlé has launched its own brand GLP-1 friendly food: Vital Pursuit. One of the products included in this brand is a cauliflower pizza that contains 32% of the recommended amount of protein. It is very good for those who are not going to eat much more in a day. The problem is that it also contains 40% of the not-to-be-exceeded amount of sodium and saturated fat. With a couple of dishes like this in the day, we would almost be over. A supposedly healthy smoothie could provide more calories and cholesterol than a donut It also mentions Smoothie King brand shakes. This includes a vanilla one that provides a highly recommended amount of protein and fiber, without added sugar. Instead, it contains more calories, sodium … Read more

If the alcohol industry didn’t already have enough problems, it has now encountered one more: Ozempic

by

Drugs from the family of GLP-1 (glucagon-like peptide 1) hormone agonists such as Ozempic or Zepbound have represented a revolution in the global pharmaceutical market. The success of these medications intended for the treatment of diabetes has to do with their slimming effect, but the ramifications of this phenomenon go even further. There is already evidence. One of these ramifications has to do with alcohol consumption: a study from a few months ago found evidence that semaglutide, the active compound used in drugs such as Ozempic or Wegovy, can also help in the treatment of alcohol addiction. New studies confirm it: In 2026 The Lancet published a larger, longer trial with 108 participants, half on semaglutin and half on placebo for 26 weeks. The result was that people who took semaglutide reduced the days of heavy consumption by 41.1% compared to 26.4% of those who took the placebo. Chronicle of a social phenomenon. Ozempic began to gain popularity about two years ago when it was beginning to be used not to keep glycemic levels under control in people with type II diabetes, but as a weight loss treatment for both people with diabetes and those who just wanted to lose weight. In parallel, several clinical trials supported this effect and regulatory bodies approved the use of the drug for this second use. This success led to the appearance of other side effects associated with this compound, some of them positive. It was then that some laboratories got to work to test these effects. Among them an apparent reduction in alcohol consumption among those who were under this treatment. How does it work? The GLP-1 hormone plays several functions in our body, one of them being to tell us that we have satisfied our appetite. That is why drugs that work like their analogues in our body generate the same feeling of satiety, which in turn implies that we will eat less and therefore lose weight. But soon some users began to realize that this not only affected the food, but also the alcohol they consumed. Although the mechanism is not entirely clear, it can be assumed that the same mechanisms are at work. There is another factor to take into account, and that is that among the side effects Of drugs similar to Ozempic we can find stomach symptoms such as nausea and vomiting. This can also lead to making alcoholic beverages, as well as other foods, less palatable. That’s what studies are like. These studies are carried out through a randomized placebo-controlled trial. That is to say, is distributed randomly participants into two groups: one is treated with semaglutide and the other with a placebo. They thus found that the effects of the treatment were greater than those of a simple placebo, that is, the participants drank less alcohol. Although the number of days on which the participants drank was not reduced, they did so in smaller volumes. “These data suggest the potential for semaglutide and similar drugs to fill an existing need for a treatment for alcohol use disorder,” explained in a press release Klara Klein in the first published study on this, member of the team responsible for the study. “Larger studies (…) are necessary to fully understand safety and efficacy in people with (this) disorder, but these initial results are promising.” The team presented the details of the trial in an article in the magazine JAMA Psychiatry. The analyzes continue. The small sample size in this study suggests that there is still much work to do. If we want to better understand the potential of Ozempic to fight addictions and similar disorders, experiments with larger samples and studies will be needed to better understand the underlying biological mechanisms, as well as the potential risks of this use. All this while other teams investigate other potential risks and benefits of this family of drugs. An example of the potential benefits yet to be explored is in heart healtha context in which we have begun to see some potential benefits but which, as in the case of excessive alcohol consumption, we still need to explore further, but the first studies seem to go in the same direction. In Xataka | On Tinder there is a trend that is gaining weight among Generation Z: dating without a single drop of alcohol Image | Andreas M / Chemist4U

We thought that Ozempic was only good for losing weight. Its last side effect is a brake on violent impulsivity

by

If there is a family of medications that has made headlines in recent years, it is the GLP-1 receptor agonists, although they will probably be more familiar to you if we say ‘Ozempic‘ either ‘wegovy‘. These drugs began by revolutionizing the treatment of type 2 diabetes, but it was all a very effective way to ‘treat’ obesity. But soon after, scientists began to notice something fascinating when they saw that patients said they also lost the desire to drink. alcoholsmoking or nail biting. After investigating it. A new studyor have taken these first indications of the suppression of impulses one step further, entering the field of crimonology and have seen that it can be a way to reduce violent crimes. To reach this point, the researchers analyzed, through a survey, 821 adults who had used GLP-1 drugs at some point. After this, the study separately analyzed current users of these medications with former users to see exactly the effect the medication can have on points that go beyond food consumption. The results. What they found is not that Ozempic “reduces crime,” but something much more subtle: in current users, the association between impulsivity traits or alcohol consumption and violent behavior was significantly weaker. That is, the drug seems to act as a buffer, since in an unmedicated person, high impulsivity combined with alcohol consumption is usually a cocktail that facilitates aggressive behavior, since something that is well proven is the relationship between alcohol and violence. But in patients under treatment with Ozempic, this transition between “feeling the impulse” and “executing the violent action” seems to be attenuated, which could prevent the transition to committing a crime of intent. Because? To understand why a metabolic drug could have behavioral effects, we have to look at the brain, since GLP-1 agonists act on brain areas involved in the reward system and appetite regulation. The clinical context of this phenomenon is increasingly documented, since a randomized, double-blind, placebo-controlled trial published in JAMA Psychiatry demonstrated that semaglutide reduced craving and several drinking metrics in adults with alcoholism disorder. This medical trial has much greater causal weight than the criminological study and provides a solid clinical basis by pointing out that GLP-1 modulates our relationship with substances and immediate gratification. With violence. With all this we can make it clear that, if on the one hand alcohol is reduced and on the other the impulsivity felt when thinking about committing a crime, indirectly two of the main catalysts of violence are being reduced. The small print. With these types of findings, it is easy to fall into sensationalism and think that we are facing the ‘Clockwork Orange’ pill. However, it must be emphasized that the published study is observational and cross-sectional in nature. This means that a kind of ‘still photo’ of the situation has been taken without following up on the participants to see how their impulsivity evolves over time. Images | David Trinks In Xataka | We thought Ozempic was only for weight loss. Science is seeing that it can end alcoholism

“Exercise cannot be optional for those taking Ozempic”

by

The classic and generally effective recipe for losing weight is summarized in two combined measures: taking care of your diet and increasing physical exercise to tip the calorie balance until it becomes negative. That is the canonical formula, but the arrival of drugs like Ozempic, wegovy o Mounjaro has turned it upside down. So much so that we are even giving up those basics. Thus, a paradoxical fact occurs: there are people losing weight (with Ozempic and similar) and exercising less. This indicates the breakdown of a healthy metabolic virtuous circle: losing weight invites us to move more, which in turn promotes weight loss. Thinner. Less athletes. a study presented at the prestigious annual meeting of the Endocrine Society (ENDO 2026) evidence that adults with obesity who lost weight with GLP-1 receptor agonist drugs have significantly reduced their physical activity. That is, after losing weight they exercise less. More specifically: when analyzing 753 patients with obesity and the data from their respective activity bracelets, it was discovered that daily steps fell from 5,047 to 4,487 (560 fewer steps) and the time of moderate or intense exercise fell from 27.9 to 22.2 minutes per day. Those who reduced their activity the most were men and those people with joint or muscle pain. Why is it important. Because these Ozempic-type drugs are not limited to reducing body fat, but can also contribute to losing lean muscle mass: a body composition analysis of the STEP 1 trial points out that weight loss with semaglutide corresponds to a reduction in lean mass of up to 40% of the total weight lost. That is why physical activity is essential to maintain strength and general health. If these people move less, the problem worsens. From a public health perspective, the need to offer explicit exercise prescription to the millions of people who take these drugs is imperative. As explains Dr. Sajana Maharjanlead author of the study: “The findings of our study reinforce the idea that exercise cannot be optional for people taking these medications. Specific interventions that encourage physical activity along with obesity medication are needed.” Context. GLP-1 receptor agonist drugs act in the brain by reducing the feeling of hunger and, as a consequence, caloric intake. What was not clear until now is its effect on the desire to move. There is previous animal studies who had already suggested that GLP-1 can reduce locomotor activity by acting on the dopaminergic reward system, for example, in micebut this work transfers it to humans with real information. Until now, studies on physical activity in patients treated with Ozempic and similar drugs have used questionnaires that people fill out alone, which opens the door to overestimation of actual exercise. However, for this work They have combined real data from Fitbit with the NIH All of Us program. In detail. Of the 1,950 patients who started treatment, only 753 had sufficient fitness tracker data for analysis. The sample presented a relevant heterogeneous case mix: 81.9% had musculoskeletal pain, 67.3% had hypertension and 48.1% had type 2 diabetes, which adds an important bias since they are complex patients with reasons to move little, with or without the drug. 560 fewer steps may not seem like much compared to the recommended daily total (friendly reminder: They are not the mythical 10,000 steps) of the WHO, but it has its importance: if the minimum ideal around 7,000 – 8,000 steps daily to obtain cardiovascular benefit and these patients are already below, any additional reduction takes them even further away from the minimum health goals. Yes, but. The study has some important limitations. To begin with, there is no control group (obese patients who did not take this type of drug), so although this is an important clue, it cannot be said with certainty that the drop in activity is caused by the drug and not another factor. Besides, the sample is heavily biased towards women (almost 8 out of 10) and towards people who already used Fitbit regularly, who do not represent all patients with obesity. In Xataka | Ozempic’s great challenge is the rebound effect. Science already has two promising solutions to avoid it In Xataka | We thought Ozempic was only for weight loss. Science is seeing that it can end alcoholism Cover | Flickr and Gabin Vallet

Festivals turned food trucks into a money-printing machine. Now they have a problem: Ozempic

by

During the marathon days of the past Coachellaone of the most important music festivals in the world where, paradoxically, music is the least important thing, an image caused a certain sensation on social networks: the total absence of lines at the food stalls. To the plethora of content generated by the festival, a showcase for social networks where only the show by Niece Carpenter and the revival by Justin Bieber caught some attention strictly musically, we had to add the “get ready with me” on Instagram and the usual parade of looks themed, generally quite unsuitable for the Californian desert. In the background a silent revolution was brewing. Because within this hyperaesthetic ecosystem there was a shadow. In the videos of many influencers and tiktokers We were able to observe a scene repeated day after day: non-existent queues to get food (even when it’s free), facing crowded lines to buy sunglasses or other accessories. For many, the reason was obvious: Ozempic. We can interpret it from irony or, on the contrary, as a clear cultural symptom that is deeper and difficult to ignore. Because, if something seems evident, it is that, in a festival where consuming aesthetics is much more important than consuming food, the Ozempic era has found its best showcase. Less hunger = less business Anyone who’s been to a festival, especially in recent times, knows what it’s like. Until recently we went with our eyes closed and our wallets open, assuming that, in addition to the increasing price of admission, we had to pay absurd amounts for a cold burger or a pad thai stale at Michelin star price. We got into the game and no one was surprised by the exorbitant prices, those 20 euros on average per plate were part of the ritual of the festival experience; but something has started to change at Coachella. To get an idea of ​​the importance of this change: the economic volume of its gastronomic industry covers more than 100 positions. Ozempic and derivatives are completely redefining the cultural codes of the last decade. Starting from the basis that each person does with their body what they consider, it is true that we were already noticing in red carpets and derivatives that curves are beginning to go out of fashion; with bloody examples because they are carried out by former standard-bearers of the movement curvy. Actresses and artists like Rebel Wilson, Barbie Ferreira either Meghan Trainor show a change in their figure that advances from photocall in photocall. Little by little this permeates society; and also leaves a side effect that someone may consider unexpected. It is not only transforming bodies but also habits and, among them, our relationship with food in spaces of mass leisure. This change in the psychological relationship that we establish with food and the hunger-suppressing effect means that this character is eliminated from the equation. hedonist and impulsive. If the desire for food ceases to exist, the key turn occurs. For years festivals were governed by a simple rule: the economic margin is not so much in the entrance, but rather in everything that happens inside. In this mechanism, food is a key element with these inflated prices, encouraging impulsive decisions in marathon days that invite consumption. This is where Ozempic has broken the model at Coachella, fully attacking that impulse. In this showcase where it seems that eating is “annoying,” a drug that controls hunger is not useful, but rather more than consistent with the environment. And yes, Coachella may not be the Cruilla or the Arenal Soundbut on a large scale what is at stake is not only what the companies can bill food trucks. What is relevant is something deeper: in an environment where excess was part of the festival attraction, a model is now beginning to prevail where control, especially of the body and image, redefines spaces designed for the opposite. Ozempic and the end of hunger The impact of this medication is such that we are no longer talking about a health phenomenon, but rather a cultural phenomenon. What began as a diabetes medication, later converted into a weight loss solution, is no longer the beauty secret of the celebrities. The pharmacological equivalent of “drinking a lot of water and sleeping eight hours” has spread with universal consumption, and with this it not only transforms bodies with their corresponding physical consequencesalso behaviors. What began as a resource for the elite is now heading towards a more affordable distribution and on a large scale. Because we are not talking about a diet, but about something much more radical, deactivating one of the most basic impulses of human behavior on a large scale, and the data begins to reflect that change. At a global level, about 46 million of people already use these medications. In the United States, the number of people without diabetes who start treatment with these drugs has grown more than 700% in just four years. Today, around 12% of adults use them, with annual growth close to 30%. This impact does not remain only in the body and, if we transfer it to the context at hand, we see that it is directly reflected in consumption; These users spend 31% less on food and drink, especially on everything associated with whim and impulse (snacks, chocolate, etc.). In Spain the trend points in the same direction, approximately 6% of households are already consumers of these treatments, thus representing an expense of 5.4 billion euros annually in food and beverages. And, again, the most relevant thing is not what you spend, but on what: this hedonistic consumption falls and basic and functional products increase. With these numbers it is logical that the conversation of “surely he has lost weight thanks to Ozempic” does not die, but it is no longer limited to celebrities like Oprah, Kelly Clarkson or the native Ibai Llanos. The same statement now slips and extends to much closer environments such as the office, the … Read more

We thought Ozempic was only for weight loss. Science is seeing that it can end alcoholism

by

The famous Ozempic has been revolutionizing the treatment of type 2 diabetes for years and also has an important effect on obesity when it comes to helping patients lose weight by causing a greater satiety. However, the scientific community had long suspected that its effects went far beyond weight control and now, science has an idea that it may have an effect on alcohol. New advances. A new study published earlier this month in The Lancet ha proven that these drugs are capable of significantly reducing the days of excessive alcohol consumption in patients who have an alcoholism problem. Something that is a great milestone, since until now the evidence on the use of these drugs to treat addictions was based on small studies, but now a big change has been made by designing a trial with the maximum guarantees to find a clear relationship between taking Ozempic and the control of addiction. How it was done. For 26 weeks, researchers followed 108 adult patients who had both obesity and an alcohol use disorder. From this sample, the group treated with semaglutide once a week experienced a 41% reduction in days of heavy drinking, compared to 26% in the placebo group not taking the treatment. In addition, patients on medication consumed an average of 1,026 grams of alcohol per month, which is a significantly lower figure considering that the control group drank 1,550 grams of alcohol. And they both thought they were taking the same treatment, although that was not the case. It’s not magic. To understand why this happens, we have to go to 2023, where a study showed that semaglutide, which is the active ingredient in Ozempic, binds directly to the nucleus accumbens of mice. By doing so, it suppresses the release of dopamine induced by alcohol consumption, suppressing the reward circuit that generates satisfaction when you drink a little alcohol and that is the effect that addicts seek. In this way, if alcohol does not generate that chemical “high”, the desire to consume it disappears. The limitations. Despite the enthusiasm that this may generate for having a new treatment against alcoholism, which is an addiction that has great negative effects, we must put the brakes on a little. At a technical level, we must keep in mind that 108 people is still a relatively small group to extrapolate the results to the entire population. Furthermore, all patients who participated in the study were obese and white, which limits the generalizability of the results to patients of normal weight or other ethnicities. And as if those were not enough limitations, it should be noted that the trial was funded by the drug manufacturers and does not have follow-up data beyond week 26. Images | freepik freepic.diller on Magnific In Xataka | We thought that quenching hunger with Ozempic was the definitive remedy against obesity. Until we look at the muscle

We thought that quenching hunger with Ozempic was the definitive remedy against obesity. Until we look at the muscle

by

The revolution of drugs as they are OzempicWegovy or Mounjaro have undoubtedly marked a before and after in the approach to obesity, which previously went under the knife when measures focused on lifestyle changes failed. A priori, we are sold the idea of ​​having a very pronounced weight loss, but the reality is that many patients are falling into protein malnutrition and losing a large amount of muscle mass. We are getting more data. We do not know the drugs completely when they begin to be marketed, but as patients use them, they emerge. new side effects or situations that pharmaceutical companies had not initially imagined. Here a revealing new studywhich will be presented at the European Obesity Congress, has put figures on these effects of malnutrition that accompany successful treatments. And all this indicates that the strategy followed with Ozempic must be changed so that doctors can give precise indications of the nutritional strategy that must be followed during the treatment period to avoid serious health problems. Not having an appetite is bad. A priori, those who take Ozempic want to have less desire to eat, and for it to practically be a task that becomes an obligation in order to survive. But the problem is that people end up having too little hunger, as a new scientific study has shown. analyzed over 5,700 days of nutritional data of 332 overweight adults between July 2025 and 2026. What was seen. Of all of these, the 116 users who were taking drugs like Ozempic consumed drastically fewer calories than the control group, something that was quite expected, but the most important thing was the protein intake that plummeted when the drugs were taken. Specifically, medicated patients consumed an average of 53.8 grams of protein per day, and adjusted to their body weight, this amounts to just 0.6 g/kg/day. To put it in perspective, 88% of these patients fell well below the official recommendation of consuming 0.8 g/kg/day of protein, and far from optimal levels for preserving muscle during weight loss. The reason. Lack of hunger literally makes people skip meals, basically because they do not have that physiological need to put anything in their mouth. Here the study could see that patients taking Ozempic or similar skipped 40.4% of dinners, 31.3% of breakfasts and 30.5% of lunches. In this way, by reducing eating to a few moments of the day, it is almost impossible to achieve the around 25 grams of protein per meal that the body needs to synthesize new muscle and maintain the structure it has. It has consequences. In medicine, the fact of losing muscle mass is what is called sarcopenia and until now it was mainly associated with people who were not physically active, such as the elderly or those who were bedridden. Here scientific reviews suggest that between 25% and 40% of all the weight lost by users taking Ozempic is muscle. And in a very important proportion with respect to fat loss, making it so that almost for every two kilos of fat lost, one is muscle. In older adults or patients with type 2 diabetes, the situation is even more serious, since high doses of semaglutide accelerate sarcopenia, reducing vital metrics for longevity and quality of life, such as grip strength or walking speed. In addition, severe calorie restriction brings with it deficiencies of micronutrients such as vitamin D, vitamin B12 or iron. How to avoid it. Here, medical guidelines increasingly point to a personalized approach in which a highly nutritious diet is established to prevent the patient from having a macronutrient deficiency while losing weight. This is why it is already being recommended that during weight loss it is recommended to increase protein consumption from 1 to 1.6 grams of protein per kg of weight, prioritizing a minimum of 20-30 grams at each meal. In addition, a ban should be established on skipping meals, with eating times having to be very measured, even a little, but at different times throughout the day to avoid prolonged fasting. Maintain muscle. This should be the primary objective and that is why, along with a diet rich in protein, strength exercise with weights, bands or even calisthenics should be encouraged. In this way, the body has the signal to maintain the amount of muscle despite the fact that there is a loss of fat due to the medication. And here the objective is to lose weight, but without having to remove the bricks that are literally building our body, since if we manage to lose weight, but are left without muscle mass, the quality of life is not going to be the best. Images | Haberdoedas Anastase Maragos In Xataka | Ozempic’s “great rebound”, in figures: science reveals that the weight returns four times faster than with a diet

Danone wants to pay 1 billion for a powdered shake company. It’s his answer to Ozempic

by

Danone has announced the acquisition of Smella British shake and powder company that competed with things like Soylent or Joylent in the “complete nutrition” sector, for about 1,000 million euros. It is an earthquake in the sector, but (above all) because of what it implies. The food industry is preparing for the earthquake caused by the new GLP-1 drugs and is doing so by gobbling up everything there is for functional nutrition. What is Huel? Founded in 2015 in the United Kingdom, it had a turnover of around 250 million pounds in 2025, sells in more than 100 countries and has among its investors to Idris Elba and Jonathan Ross. But none of that explains why a company like this is worth so much money. After all, Human Fuel sells nutritionally complete meals: powders, shakes, bars and instant meals. Although the idea is that these products cover 100% of daily needs, the same company recommends complementing it with conventional food. And why does Danone want that? That’s the big question. The purchase of Huel is part of the strategy Renew Danone which, since 2022, seeks to expand and diversify the company’s work. Danone already has Nutriciaits specialized medical nutrition division (Fortimeloncological supplements, pediatric formulas), which operates in the clinical and hospital setting. With Huel, you are building a functional and specialized nutrition ecosystem that covers all steps from the clinic either probiotics to mass consumption. The central issue is that the market does not stop growing. To grow and transform. It is estimated that meal replacements move between 16,000 and 21,000 million dollars each year. and heanalysts agree in which it will grow at a rate greater than 5%. But what makes this operation more than a corporate purchase is the context. GLP-1 drugs (Ozempic, Wegovy, Mounjaro) are radically transforming food purchasing habits. Users eat less, buy less ultra-processed foods, and when they eat, they look for maximum nutritional density in every bite. According to Circana, households with LPG-1 usersThey will represent 35% of food sales in the US by 2030. Nestlé has already launched a specific line (Vital Pursuit), Conagra Label your dishes “GLP-1 Friendly” and General Mills is reformulating its products so they have more protein and fiber. And why now? Basically because Danone has money. In 2024, they had a cash flow of more than 3,000 million euros. In 2025, Danone CEO made it clear that the company wanted to “go on the offensive with acquisitions. And I have done it. In the last few years they have bought three emerging companies in key sectors (and many others that, finally, has not been able to acquire). Danone isn’t buying a smoothie maker: it’s buying a position in the new food chain the GLP-1s are creating. One where food is not sold for pleasure or convenience, but for function. Image | In Xataka | Neither Soylent nor Joylent. May the future not take away the ritual, flavor and texture of eating.

What the war in Ukraine has not achieved, Greenland has done. Europe has taken out its “commercial bazooka” against the US: Ozempic

by

For more than a year, Europe has become accustomed to living trapped in an uncomfortable balance where depends on the United States for its security through NATO, to sustain the Ukrainian effort and, ultimately, for the strategic architecture that has protected it since the Cold War. Now Greenland has done jump into the air part of the rhetoric. Europe and the counterattack. The crisis has erupted when Trump has returned to ignite a trade war using Greenland as an excuse and as an ultimatum: either some type of “agreement” that brings the island closer to the United States is accepted, or tariffs arrive first from 10% and after 25% a group of European countries designated by a minimal but symbolic gesture, to participate in Arctic maneuvers with Denmark. What until recently many in Europe preferred to interpret as bravado or negotiating tactics becomes an explicit message of political pressure that no longer leaves room for the fantasy of appeasement. And there appears the real change: what the Ukrainian war had not completely achieved (a frontal European response to American reprisals) Greenland is doing itbecause the coup is not against a geopolitical adversary but against alliesand because it puts Europe before a brutal choice: accept the blackmail and normalize it, or respond even if it hurts, even knowing that it continues to depend on Washington for its security and to contain Russia. The European bazooka. There is no doubt, the European reaction It is not born from enthusiasm, but from the feeling that there are no longer many other solutions: Greenland cannot be “handed over”, nor can Denmark sell an autonomous territory against the will of its population, and the very idea that an acquisition could be forced due to commercial threats opens a pandora’s box that affects the entire continent. In this context, Brussels dusts off for the first time his toughest tool, the so-called anti-coercion instrumentdesigned precisely to punish political pressures through rapid and forceful economic measures. on the table two paths appear that mark a leap in mentality: reactivate a package of tariffs worth of 93,000 million of euros already prepared and, if the escalation continues, go further of goods and target services, investment and even access to the European market for large American companies. The European message tries to be twofold, seeking a de-escalation that avoids an open clash, but making it clear that, if Trump turns trade into a method of extortion, Europe can also respond strongly. The crash that nobody wanted. The most disturbing thing about this episode is not only the economic impact of a tariff war, but the strategic fracture that it implies: Europe knows that a serious trade conflict with the United States will would infect NATOto Ukraine and the entire deterrence architecture against Russia. That is why the continent moves cautiouslycalling emergency meetings, preparing the ground for talks in Davos and even delaying previously agreed trade detente measures. But the core of the problem is that Trump is not negotiating a percentage or a clause: you are elevating a territorial objective to a national priority, presenting it as a requirement to “improve the security” of the Arctic, and implicitly denying that Europe can guarantee it. In this framework, Europe tries not to break the bridge, but assumes that it can no longer behave as if the bridge were indestructible. The sovereignty of Greenland. We’ve told it before: while Washington talks about “acquisition,” Greenland insists that its future belongs to them, that many they want more independencenot change flag. This point is essential because it explains why Europe doesn’t want to give in: it is not just about Danish pride or formalisms, but about sovereignty and democratic legitimacy, as well as an explosive precedent within the Union itself. The tariff threattherefore, works as an attempt to isolate Denmark and make it the weak link, although it has the opposite effect: it reinforces the idea that if you are attacked over a strategic issue, you will be respond as a block. And therein lies the paradox: instead of dividing, the pressure forces coordination, especially between Paris and Berlin, which push a harder line while others ask for time to see if Trump offers a “way out” before the punishment is activated. The “Ozempic bomb”. Amid the noise of bases, submarines and Arctic routes, the unexpected weapon appears: Denmark is not a commercial giant, but it exports products to the United States that directly affect the pocket and everyday lifeand that turns any tariff into a kind of political boomerang. The half of its sales Recent visits to Washington focus on medicines, vaccines, insulin and related products, because Novo Nordisk is there, the Danish economic engine and the factory of the global phenomenon Ozempic and Wegovy. That dependency converts Denmark in a kind of de facto “pharmaceutical state”: Your private growth and employment largely revolve around that industry, and any trade turbulence impacts both sides. If Trump makes these medicines more expensive, the blow will not stay in Europe: it enters the US market like health inflation and social unrest, just where the political margin is most fragile. And that is why Ozempic, more than a product, works as symbol of interdependence reality that makes a tariff war not just a lever, but rather a grenade. Lego and other reminders. The same effect is seen with Lego and other products Danes beloved in the United States, or with less visible but critical sectors such as hearing aids and certain medical equipment. In the real world, supply chains do not respect emotional boundaries: many parts are manufactured in different countries, assembled in others, and sold in markets that depend on global logistics. This means that tariffs punish not only the “enemy” exporter, but also companies, distributors and consumers. Trump can imagine squeezing Denmark to bend it, but the pressure leaks out in prices and disruptions in the US market itself, and also erodes the relationship with an ally that already offers military access in … Read more

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.